Press release
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Long Term Investor Alert: Investigation of potential Wrongdoing
An investigation on behalf of current long term investors in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares.
Investors who are current long term investors in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: IOVA stocks follows a lawsuit filed against Iovance Biotherapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: IOVA stocks, concerns whether certain Iovance Biotherapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Those who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Long Term Investor Alert: Investigation of potential Wrongdoing here
News-ID: 4156554 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Investors who hold shares of MicroStrategy Incorpora …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of MicroStrategy Incorporated.
Investors who are current long term investors in MicroStrategy Incorporated (NASDAQ: STRK) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: STRK stocks follows a lawsuit filed against MicroStrategy Incorporated over…
Lawsuit filed for Investors who lost money with shares of Altimmune, Inc. (NASDA …
An investor, who purchased shares of Altimmune, Inc. (NASDAQ: ALT), filed a lawsuit over alleged violations of Federal Securities Laws by Altimmune, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and for certain investors are short and strict deadlines running. Deadline: October 6, 2025. NASDAQ: ALT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Long-Term Investors in shares of Elevance Health, In …
An investigation was announced for current long-term investors in shares of Elevance Health, Inc. (NYSE: ELV) concerning potential breaches of fiduciary duties by certain directors of Elevance Health, Inc.
Investors who are current long term investors in Elevance Health, Inc. (NYSE: ELV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on August 25, 2025 in the lawsuit filed for certain investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) over alleged securities laws violations by Sarepta Therapeutics, Inc.
Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and there are strict and short deadlines running. Deadline: August 25, 2025. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
More Releases for Iovance
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit …
A deadline is coming up on July 14, 2025 in the lawsuit filed for certain investors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) over alleged securities laws violations by Iovance Biotherapeutics, Inc.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and there are strict and short deadlines running. Deadline: July 14, 2025. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Cellular Immunotherapy Market Projected To Witness Massive Growth, 2025-2032 | I …
The qualitative latest Research report (2025-2032) on the Cellular Immunotherapy Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/135590
Focused on growth and…
Lawsuit filed for Investors who lost money with shares of Iovance Biotherapeutic …
An investor, who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), filed a lawsuit i over alleged violations of Federal Securities Laws by Iovance Biotherapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and for certain investors are short and strict deadlines running. Deadline: July 14, 2025. NASDAQ: IOVA investors should contact the Shareholders Foundation at…
Endomucin Market Overall Study Report 2024-2032 | CytoDyn, Iovance Biotherapeuti …
The Endomucin Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2024 and 2032. It's like a compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future. This report becomes a strategic ally for companies, stakeholders, and industry players, offering a comprehensive…
Cervical Cancer Therapeutics Market 2023 | Futuristic Trends- Genocea, AstraZene …
This report provides an informative view about the competitive aspect of the global market. It includes detailed picture of the exhibition of a portion of the essential global players working in the Cervical Cancer Therapeutics market. The research study also provides historical record with profits predictions and forecasts from 2023 to 2029. Also, the business manufacturing of the notable manufacturers is also emphasized with technical data in the report.
This report…
Tumor Infiltrating Lymphocyte (TIL) Market Key Players and Production Informatio …
The new study on the Global Tumor Infiltrating Lymphocyte (TIL) Market 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Tumor Infiltrating Lymphocyte (TIL) industry. Because of the in-depth overview of the world Tumor Infiltrating Lymphocyte (TIL) market, the recent document allows investors, traders, and manufacturers to plan some innovative techniques, and meanwhile, align them with operational and commercial enterprise models. Additionally, the Tumor…
